Vaccines contain antigenic substances capable of inducing immunity against an infective agent or toxin.
They are frequently administered prophylactically but are increasingly being researched and developed in a therapeutic context (eg cancer vaccines which are designed to equip a patient’s immune system to treat an existing cancer).
While the global market for vaccines is less than 3% of the total pharmaceuticals market, World Health Organization research suggests that over the next few years, the vaccine market will enjoy a growth rate of 10% to 15% per year versus the 5% to 7% seen in the overall market.
To take a share of this expanding market, companies must navigate a number of challenges. The assessment, licensing and control of vaccines (which are biological medicinal products) occurs in an environment of rapid innovation and complex quality concerns. Our deep experience of vaccines, combined with the fact that our team includes lawyers with degrees in relevant scientific areas (molecular biology, biochemistry, genetics etc), enables us to quickly grasp evolving issues and technical concepts and provide nuanced and tailored advice.
We are trusted by many of the world’s leading vaccine companies to help them navigate all stages of the vaccine lifecycle. Our clients include Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer and Novartis.
News & insights
Publications: 29 NOVEMBER 2019
As more countries liberalise their cannabis policies, there has been a rapid increase in the number of registered IP rights as competitors seek to establish their places in the market.Read more
Publications: 04 OCTOBER 2019
A&O has marked the end of Q3 2019 with an outstanding performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.Read more
Publications: 28 AUGUST 2019
On 8 August 2019, the National Institute for Health and Care Excellence (NICE)1 published a draft guideline on prescribing cannabis-based medicinal products (the Draft Guideline) for consultation.2Read more
Publications: 26 JULY 2019
At a time when U.S.-China trade tensions are being reported as having a dramatic impact on the global economy, China’s Ministry of Commerce has announced that the actual use of foreign capital in China is still increasing steadily, indicating that foreign investment into China’s economy is not yet being significantly affected by the trade war. In the first half of 2019, a total of 20,131 foreign invested enterprises were newly established in China, with the actual deployment of foreign capital reaching RMB478.33 billion, an increase of 7.2% year on year (equivalent to USD70.74bn, up 3.5% year on year) (excluding the data in the banking, securities and insurance sectors).Read more